Literature DB >> 11100360

Does surveillance for hepatocellular carcinoma in HCV cirrhotic patients improve treatment outcome mainly due to better clinical status at diagnosis?

E Giannini1, L Arzani, P Borro, F Botta, A Fasoli, D Risso, G Celle, R Testa.   

Abstract

BACKGROUND/AIMS: Cirrhotic patients with hepatitis C virus infection are a group at higher risk for hepatocellular carcinoma. Conventional screening programs detect only few early hepatocellular carcinomas that are eligible for radical treatment. Our aim was to compare characteristics of patients, modality of treatment, and outcome in anti-HCV positive cirrhotics with hepatocellular carcinoma diagnosed during follow-up, or incidentally.
METHODOLOGY: Sixty-one hepatocellular carcinomas were consecutively diagnosed in cirrhotic anti-HCV patients from 1993-1998 among which 34 during biannual ultrasonographic-biochemical follow-up and the others incidentally. Child-Pugh's score, alpha-fetoprotein levels, uni- or multifocality of the tumor, and treatment and survival of the patients were then analyzed on the basis of modality of diagnosis.
RESULTS: Surgical treatment was feasible only in a minority of patients. Radical and palliative treatment was more frequent among patients with HCC diagnosed during follow-up. Child-Pugh's score was lower in these patients, moreover their survival rate was better. Analysis of survival of patients treated with the same procedure and grouped by modality of diagnosis did not demonstrate any differences. Regression analysis showed that patients with a lower Child-Pugh's score, one nodule, with a tumor diagnosed during follow-up and who were treated had a better survival rate.
CONCLUSIONS: In our population surveillance did not detect a higher percentage of curable HCC. Nevertheless the results of palliative treatment and of curative treatment overlapped. Overall better outcome was observed in patients with preserved liver function whatever the treatment. Surveillance allowed us to diagnose HCC in patients with these characteristics thus leading to an improved survival rate.

Entities:  

Mesh:

Year:  2000        PMID: 11100360

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  7 in total

1.  Surveillance for hepatocellular carcinoma in liver cirrhosis: have programmes improved because patients have?

Authors:  E Giannini; R Testa
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

2.  Surveillance for hepatocellular carcinoma in liver cirrhosis: have programmes improved because patients have?

Authors:  E Giannini; R Testa
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

3.  No Association Between Screening for Hepatocellular Carcinoma and Reduced Cancer-Related Mortality in Patients With Cirrhosis.

Authors:  Andrew M Moon; Noel S Weiss; Lauren A Beste; Feng Su; Samuel B Ho; Ga-Young Jin; Elliott Lowy; Kristin Berry; George N Ioannou
Journal:  Gastroenterology       Date:  2018-07-05       Impact factor: 22.682

4.  Effectiveness of surveillance for hepatocellular carcinoma in clinical practice: A United States cohort.

Authors:  Sahil Mittal; Fasiha Kanwal; Jun Ying; Randy Chung; Yvonne H Sada; Sarah Temple; Jessica A Davila; Hashem B El-Serag
Journal:  J Hepatol       Date:  2016-07-29       Impact factor: 25.083

5.  Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review.

Authors:  Ryosuke Tateishi; Haruhiko Yoshida; Yutaka Matsuyama; Norio Mine; Yuji Kondo; Masao Omata
Journal:  Hepatol Int       Date:  2007-12-29       Impact factor: 6.047

Review 6.  Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies.

Authors:  Puneeta Tandon; Guadalupe Garcia-Tsao
Journal:  Liver Int       Date:  2008-12-24       Impact factor: 5.828

7.  Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis.

Authors:  Amit G Singal; Anjana Pillai; Jasmin Tiro
Journal:  PLoS Med       Date:  2014-04-01       Impact factor: 11.069

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.